EGFR and glioblastoma: Specifically, antibody-targeted liposomes, such as EGFR-targeted sgPLK1-cLNPs, have been developed to deliver Cas9/sgRNA RNP to GBM cells, enhancing targeted gene editing and potentially improving therapeutic outcomes for this aggressive brain tumor [47].